Trial Profile
Angiographic outcomes of bioresorbable-polymer everolimus-eluting (Synergy) stents compared to durable-polymer everolimus-eluting (Xience) stents in patients with coronary artery disease
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 25 Nov 2016
Price :
$35
*
At a glance
- Drugs Everolimus (Primary)
- Indications Coronary artery disease; Coronary artery restenosis
- Focus Adverse reactions
- 25 Nov 2016 New trial record